



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 March 2015
EMA/CVMP/128685/2015
Committee for Medicinal Products for Veterinary Use

Summary of opinion¹ (post-authorisation)

Broadline

International non-proprietary name (INN): Fipronil, eprinomectin, praziquantel, (S)-methoprene

On 12 March 2015, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion², recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Broadline. The marketing authorisation holder for this veterinary medicinal product is Merial.

The change agreed by the CVMP concerns the addition of the following new therapeutic indications in the target species (cats):

- Treatment of infestations with feline lungworms (L3 and L4 larvae, and adults of *Aelurostrongylus abstrusus*); and
- Treatment of notoedric mange (*Notoedres cati*)

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

